Inclusion of Rituximab in Treatment Protocols for Non-Hodgkin's Lymphomas and Risk for Progressive Multifocal Leukoencephalopathy

被引：38

作者：

Tuccori, Marco ^{[1
]}

Focosi, Daniele ^{[2
]}

Blandizzi, Corrado ^{[1
,5
]}

Pelosini, Matteo ^{[2
]}

Montagnani, Sabrina ^{[1
,5
]}

Maggi, Fabrizio ^{[3
,4
]}

Pistello, Mauro ^{[3
,4
]}

Antonioli, Luca ^{[1
]}

Fornai, Matteo ^{[1
]}

Pepe, Pasquale ^{[6
]}

Rossi, Giuseppe ^{[6
]}

Petrini, Mario ^{[2
]}

机构：

[1] Univ Pisa, Dept Internal Med, Div Pharmacol & Chemotherapy, Pisa, Italy

[2] Univ Pisa, Div Haematol, Dept Oncol Transplantat & New Technol Med, Pisa, Italy

[3] Univ Pisa, Virol Sect, Pisa, Italy

[4] Univ Pisa, Retrovirus Ctr, Dept Expt Pathol, Pisa, Italy

[5] Tuscan Reg Ctr Pharmacovigilance, Pisa, Italy

[6] CNR, Unit Epidemiol & Biostat, Inst Clin Physiol, Pisa, Italy

来源：

ONCOLOGIST | 2010年 / 15卷 / 11期

关键词：

Rituximab; Progressive multifocal leukoencephalopathy; JCV; Monoclonal antibody; Non-Hodgkin's lymphoma; ADVERSE DRUG EVENTS; NATALIZUMAB; EFALIZUMAB; THERAPY; PROJECT; DISEASE; PML;

D O I：

10.1634/theoncologist.2010-0098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives. Rituximab is an anti-CD20 monoclonal antibody that promotes better treatment outcomes in patients with non-Hodgkin's lymphoma (NHL). Case series of progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab within polychemotherapy regimens have led to the introduction of a black box warning, but no risk estimation has ever been provided. Methods. We performed a retrospective, monocentric cohort study on 976 NHL patients diagnosed in 1994-2008, including 517 patients who received at least one dose of rituximab. Results. Inclusion of rituximab into standard chemotherapy regimens for NHL caused a significantly higher incidence of PML cases (rate difference, 2.2 every 1,000 patient-years; 95% confidence interval, 0.1-4.3). Interpretation. Based on this finding, clinical surveillance of PML-related symptoms is recommended in NHL patients exposed to rituximab. The Oncologist 2010;15:1214-1219

引用

页码：1214 / 1219

页数：6

共 50 条

[31] Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia [J].

Bello, Celeste ;

Veliz, Marays ;

Pinilla-Ibarz, Javier .

EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (03) :295-300

[32] Use of Rituximab in Combination with Conventional Chemotherapy for the Treatment of Non-Hodgkin's Lymphoma of the Head and Neck [J].

Manolopoulos, Leonidas ;

Gomatos, Ilias P. ;

Leandros, Emmanuel ;

Alevizos, Leonidas ;

Georgiou, Natasa ;

Giotakis, John ;

Ferekidis, Eleutherios .

IN VIVO, 2009, 23 (03) :475-478

[33] The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma [J].

Smolewski, Piotr ;

Robak, Tadeusz .

EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (07) :791-808

[34] Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma [J].

Arredondo-Garza, Teresa ;

Majluf-Cruz, Abraham ;

Vela-Ojeda, Jorge ;

Mariscal-Ramirez, Ignacio ;

Solis-Anaya, Luis ;

Refugio Lopez-Gutierrez, Jose ;

Hernandez Guadarrama, Cesar ;

Rico-Curiel, Enrique ;

Armenta-San Sebastian, Jorge Antonio ;

Castaneda-Hernandez, Gilberto .

ARCHIVES OF MEDICAL RESEARCH, 2013, 44 (07) :549-554

[35] A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas [J].

Feugier, Pierre .

FUTURE ONCOLOGY, 2015, 11 (09) :1327-1342

[36] Relationship between Hodgkin's and non-Hodgkin's lymphomas [J].

Amini, RM ;

Enblad, G .

MEDICAL ONCOLOGY, 2003, 20 (03) :211-220

[37] Relationship between Hodgkin’s and non-Hodgkin’s lymphomas [J].

Rose-Marie Amini ;

Gunilla Enblad .

Medical Oncology, 2003, 20 :211-220

[38] The therapeutic use of rituximab in non-Hodgkin's lymphoma [J].

Marcus, Robert ;

Hagenbeek, Anton .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 78 :5-14

[39] Rituximab zur Therapie des Non-Hodgkin-LymphomsRituximab for the therapy of non-Hodgkin’s lymphoma [J].

M.J. Rummel .

Der Onkologe, 2007, 13 :227-235

[40] Rapid-progressive decrease of cognitive and physical functions in a B-cell non-Hodgkin's lymphoma patient treated with rituximab/bendamustine [J].

Kuellmer, A. ;

Herrmann, G. ;

Riecken, B. .

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2013, 138 (25-26) :1355-1359

← 1 2 3 4 5 →